About
Weight Method connects every patient with licensed providers who specialize in obesity medicine. No generic algorithms, no auto-approvals — every treatment plan is individually reviewed.
Weight Method's medical team includes board-certified obesity medicine specialists and licensed healthcare providers across all 50 states. Every treatment plan is individually reviewed by a qualified provider. Our protocols are based on FDA-approved GLP-1 medications backed by landmark clinical trials including STEP 1 and SURMOUNT-1.
Our network includes multiple licensed medical professionals across the United States, ensuring coverage and expertise in every state.
Certifications from the American Board of Obesity Medicine (ABOM) or equivalent bariatric medicine specialties.
Active medical licenses verified through state medical boards and re-validated periodically.
Physicians with specific expertise in weight management and metabolic conditions.
Education focused on GLP-1 pharmacology, dosing protocols, and patient management.
Every patient receives an individualized medical evaluation to ensure GLP-1 treatment is safe and appropriate.
Detailed medical questionnaire: BMI, pre-existing conditions, current medications, prior GLP-1 history, and contraindications.
Objective clinical criteria: BMI ≥ 30, or BMI ≥ 27 with qualifying comorbidities. Patients under 18 are not eligible.
A licensed medical provider personally reviews every case, selects medication, and determines initial dosing.
Semaglutide or tirzepatide based on BMI, medical history, and expected response. Gradual escalation dosing.
Progress tracking, dosing adjustments, and continuous support throughout the program.
Key Fact
Every treatment plan is individually reviewed by a licensed medical provider. No auto-approvals or algorithm-only systems are used.
Protocols built on landmark clinical trials published in the world's most prestigious medical journals.
Semaglutide 2.4 mg vs 2.4% placebo over 68 weeks in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with comorbidity.
Wilding JPH, et al. N Engl J Med. 2021;384:989-1002. DOI: 10.1056/NEJMoa2032183
Tirzepatide 15 mg at 72 weeks in adults with obesity. The largest reduction recorded in a GLP-1 clinical trial.
Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. DOI: 10.1056/NEJMoa2206038
Semaglutide 2.4 mg over 68 weeks, demonstrating efficacy even where weight loss is clinically more challenging.
Davies M, et al. Lancet. 2021;397(10278):971-984. DOI: 10.1016/S0140-6736(21)00213-0
Tirzepatide at 72 weeks, significantly outperforming previous therapies in this population.
Garvey WT, et al. Lancet. 2023;402(10402):613-626. DOI: 10.1016/S0140-6736(23)01200-X
Key Fact
The STEP and SURMOUNT trials represent over 10,000 combined participants and demonstrate 14.9%–22.5% body weight loss with semaglutide and tirzepatide.
Source: New England Journal of Medicine, The Lancet
Weight Method operates under strict regulatory compliance and patient protection standards.
Semaglutide (Wegovy) and tirzepatide (Zepbound) with full regulatory approval for chronic weight management.
Licenses validated before onboarding and re-verified periodically.
Medical data encrypted in transit and at rest with strict access controls.
Telehealth, medication, HIPAA, and terms consents — all electronically signed.
Identity verified and eligibility confirmed before prescribing. No shortcuts.
AACE and Endocrine Society guidelines with individualized adjustments.
Take our 5-minute quiz and a licensed provider will review your eligibility for GLP-1 treatment.
Check Eligibility